Catapult Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Catapult Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$1.47M	Sell	25,954 -76,877	-75%	-$4.98M	0.55%	68
2015 Q2	$6.08M	Sell	102,831 -363,908	-78%	-$22.4M	0.87%	24
2015 Q1	$29.1M	Buy	466,739 +276,739	+146%	+$16.1M	3.56%	2
2014 Q4	$10.9M	Buy	190,000 +65,000	+52%	+$3.62M	2.78%	5
2014 Q3	$6.72M	Sell	125,000 -10,000	-7%	-$530K	0.72%	50
2014 Q2	$7.08M	Sell	135,000 -150,000	-53%	-$7.67M	0.79%	27
2014 Q1	$15.1M	Buy	+285,000	New	+$13.2M	3.01%	5

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Catapult Capital Management's TEVA Position: Q3 2015 in Review

Catapult Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 75% in Q3 2015, selling an estimated $4.98M and leaving 25,954 shares worth $1.47M. The position accounts for 0.55% of the portfolio, ranked #68.

Catapult Capital Management first reported a position in TEVA in Q1 2014 and has held it in 7 quarters since. The position peaked at $29.1M in Q1 2015. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Catapult Capital Management held 25,954 shares of Teva Pharmaceuticals worth $1.47M as of Q3 2015.
Catapult Capital Management sold 76,877 Teva Pharmaceuticals shares in Q3 2015, an estimated $4.98M.
Teva Pharmaceuticals made up 0.55% of Catapult Capital Management's portfolio in Q3 2015, its #68 holding.
Catapult Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 7 quarters since.
Catapult Capital Management's Teva Pharmaceuticals position peaked at $29.1M in Q1 2015.
824 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.